在三阴性乳腺癌的秘鲁患者接受新辅助化疗后,HER2 变化对生存结果的影响
Zaida Morante1,2, Yomali Ferreyra3,4, Iris Otoya2
1Faculty of Human Medicine, Cayetano Heredia Peruvian University, Lima, Peru.
The breast journal
|November 24, 2025
概括
在新辅助化疗 (NAC) 后的人类表皮生长因子受体2 (HER2) 状态的变化没有影响秘鲁三阴性乳腺癌 (TNBC) 患者的生存结果. 在接受NAC.的TNBC患者中,HER2状态转换没有被发现是预后性的.
科学领域:
- 在瘤学瘤学.
- 医学遗传学 医学遗传学
- 临床研究 临床研究
背景情况:
- 三阴性乳腺癌 (TNBC) 往往缺乏人体表皮生长因子受体2 (HER2) 表达,限制了向治疗选择.
- 在新辅助化疗 (NAC) 后HER2状态的变化已被记录,但它们在秘鲁TNBC患者的预后意义尚不清楚.
研究的目的:
- 评估在秘鲁TNBC患者中NAC前后的HER2表达状态.
- 确定HER2状态变化与临床特征,治疗反应和生存结果之间的关联.
主要方法:
- 分析了159名接受NAC (2015-2019) 的TNBC患者的临床病理学数据.
- 后勤回归评估了基线HER2状态和病理完整反应 (pCR) 之间的联系.
- 科恩的卡帕和卡普兰-梅尔分析评估了HER2状态一致性和生存 (OS,DFS) 影响.
主要成果:
- 40.3%的TNBC患者在诊断时HER2低;14.9%实现了PCR.
- 在NAC前的HER2状态与pCR没有相关性 (OR=1.4,p=0.5).
- 在NAC后的HER2状态一致性是中度的 (科恩的kappa=0.3418,p<0.001). 在HER2状态转换时没有显著的OS或DFS改善.
结论:
- 在NAC后的HER2状态转换可能不是TNBC患者的显著预后因素.
- 这些发现表明,HER2表达动态不会影响这一特定患者队列的生存率.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
17.0K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
相关概念视频
01:21Cancer Survival Analysis
633
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K